Navigation Links
PDS Biotechnology Corporation Finalizes Commercial Licensing Agreement with Merck Eprova AG to Utilize Merck Eprova's Enantiomers of DOTAP Chloride in Immunotherapies
Date:2/24/2009

INDIANAPOLIS, Feb. 24 /PRNewswire/ -- PDS Biotechnology today announced that the company has obtained an exclusive license from Merck Eprova AG to utilize Merck Eprova's proprietary chiral lipid DOTAP Chloride in Versamune(TM)-HPV and other products in development based on the Versamune(TM) technology. The use of enantiomerically pure DOTAP Chloride shows enhanced adjuvant activity compared to the racemate. Merck Eprova AG will be providing enantiomerically pure DOTAP Chloride manufactured under cGMP for use in clinical and commercial drug products developed with PDS Biotechnology's Versamune(TM) nanoparticle technology. PDS Biotechnology will own the intellectual property rights to products incorporating the chiral DOTAP lipids for immunotherapeutic applications.

Versamune(TM)-HPV is an immunotherapy drug which has demonstrated significant promise in curing HPV infection and HPV-related cancer in preclinical animal and human model studies. Cancers caused by infection with the human papilloma virus (HPV) include cervical, head and neck and anal cancers. No cures exist for these cancers. Based on promising in vivo and in vitro efficacy data, PDS Biotechnology has been awarded grants by the US National Institutes of Health/National Cancer Institute to develop Versamune(TM)-HPV and Versamune(TM)-Melanoma. Versamune(TM)-Melanoma is being developed to treat melanoma, which is the most aggressive form of skin cancer.

PDS Biotechnology's Versamune(TM) nanotechnology facilitates the uptake of disease-associated protein and peptide antigens by the antigen-presenting cells of the immune system. Simultaneously it acts as a strong immune system activator (adjuvant) without the inflammatory side effects induced by current adjuvants. The result is simple, safe and cost effective nanotechnology-based drugs and vaccines that induce effective eradication of the specific cells infected with, or expressing the particular protein formulated with Versamune(TM).

PDS Biotechnology Corporation (www.pdsbiotech.com) is an Indiana-based biotechnology company applying the company's proprietary Versamune(TM) nanotechnology drug platform technology to the development of safe and potent immunotherapies to prevent and to treat cancer and diseases caused by infectious agents.

Merck Eprova AG (www.merckeprova.com), located in Schaffhausen, Switzerland, is a wholly owned subsidiary of Merck KGaA located in Darmstadt, Germany. Merck Eprova AG specializes in the development and production of cGMP grade, highly purified and characterized Drug Delivery Compounds such as cationic lipids, PEGs, PEG-lipids, and phospholipids. In addition Merck Eprova AG is a centre of excellence for reduced folates in the pharmaceutical and nutritional field and the world's leading supplier of reduced folates.


'/>"/>
SOURCE PDS Biotechnology
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Yongye Biotechnology Announces Preliminary Results for Fiscal Year 2008
2. Yongye Biotechnology to Host Virtual Retail Road Show to Provide Overview of the Company in English and Mandarin
3. Yongye Biotechnology International to Expand its Network of Branded Stores
4. Biotechnology Value Fund, L.P. Requests Avigen Board to Provide Critical Information to Stockholders
5. Yongye Biotechnology to Present at Roth Conference
6. MannKind to Present at the 11th Annual Biotechnology Industry Organization BIO CEO & Investor Conference
7. Energy, Biotechnology and Agribusiness Veterans Form SG Biofuels to Develop Jatropha as Low-Cost, Sustainable Oil
8. Fraunhofer USA Center for Molecular Biotechnology Receives Gates Foundation Grant for Avian Influenza Vaccine Development
9. BVF Acquisition LLC, a Wholly-Owned Subsidiary of Biotechnology Value Fund, L.P., Commences Tender Offer for Any and All Outstanding Shares of Avigen at $1.00 Per Share
10. InVitria Among Leading Innovators in Cell Culture Media According to Top Biotechnology Publication
11. TaiGen Biotechnology Secures 37 Million USD in Series C Round Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... International research firm Parks Associates announced today that Tom ... 2017 Annual Meeting , October 11 in Scottsdale, Arizona ... and how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and ...
(Date:10/10/2017)... (PRWEB) , ... October 10, 2017 , ... ... recipients of 13 prestigious awards honoring scientists who have made ... in a scheduled symposium during Pittcon 2018, the world’s leading conference and exposition ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board ... Stubbs, a professor in Harvard University’s Departments of Physics and Astronomy, has been selected ... member of the winning team for the 2015 Breakthrough Prize in Fundamental physics for ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... and applications consulting for microscopy and surface analysis, Nanoscience Instruments is now ... Analytical offers a broad range of contract analysis services for advanced applications. ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... to expand at a CAGR of 25.76% during the ... is the primary factor for the growth of the ... https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global stem ... technology, application, and geography. The stem cell market of ...
(Date:3/30/2017)... March 30, 2017 Trends, opportunities and forecast ... behavioral), by technology (fingerprint, AFIS, iris recognition, facial recognition, ... others), by end use industry (government and law enforcement, ... and banking, and others), and by region ( ... Asia Pacific , and the Rest ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
Breaking Biology News(10 mins):